Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Environmental Impacts of Pharmaceuticals: A New Approach to Research

By WILEY | January 28, 2016

Researchers have developed a new way to prioritize investigations on the environmental impacts of the estimated 1500 active pharmaceutical ingredients currently in use.

Little is known about the potential impact these drugs may have on the environment in terms of risks to aquatic and soil organisms, avian and mammalian wildlife, and humans, and it is unrealistic to study all 1500 concurrently. When investigators applied their new approach to 146 active pharmaceuticals that are either used in the community or in hospital settings in the United Kingdom, they identified 16 compounds as a potential priority. These substances include compounds belonging to the antibiotic, antidepressant, anti-inflammatory, antidiabetic, antiobesity, and estrogen classes.

“Many approaches have been proposed in the past for prioritizing pharmaceuticals in the environment. This is the first time a holistic approach has been proposed that considers all the main environmental compartments and trophic levels,” said Dr. Alistair Boxall, senior author of the Environmental Toxicology & Chemistry article. “Application of the approach should really allow us to identify which pharmaceuticals warrant further scrutiny.”

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Related Articles Read More >

Diverse factory workers in yellow PPE suits checking production data with clipboard in modern industrial facility, Quality control inspector wearing masks and hairnets working in food or pharma plant
ISO 9001, 14001 and 45001 revisions: What changes and when to start
Artis BioSolutions announces new center of excellence in Spain
Bristol Myers Squibb’s RazyeBio to build $173 million Indiana facility 
Bristol Myers Squibb to build new plant in Houston 
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE